18F-TPP for Membrane Potential Imaging

SH
KT
Overseen ByKristen Torres, BS
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

In this study, investigators propose to use PET imaging to study the pharmacokinetics of 18F-TPP and develop methods for imaging membrane potential (ΔΨT) in humans.

Who Is on the Research Team?

GE

Georges El Fakhri, PhD, DABR

Principal Investigator

Yale University

Are You a Good Fit for This Trial?

Inclusion Criteria

* Willing and able to give voluntary written informed consent
I am willing and able to follow all study procedures and be available for the study duration.
I am in good overall health based on recent medical tests.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging and Pharmacokinetics Assessment

Assessment of the pharmacokinetics of 18F-TPP using PET imaging, including potential arterial blood sampling for radioactivity analysis

Up to 90 days
Multiple visits for PET/CT and MRI scans

Follow-up

Participants are monitored for safety and effectiveness after imaging procedures

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • 18F-TPP

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: 18F-TPPExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials
1,963
Recruited
3,046,000+

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

Collaborator

Trials
102
Recruited
21,600+